| Sharon Mayes, | |
|
14701 E Exposition Ave, Aurora, CO 80012-2623 | |
| (303) 743-5855 | |
| Not Available |
| Full Name | Sharon Mayes |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 14701 E Exposition Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700072063 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 20847 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sharon Mayes, 14701 E Exposition Ave, Aurora, CO 80012-2623 Ph: () - | Sharon Mayes, 14701 E Exposition Ave, Aurora, CO 80012-2623 Ph: (303) 743-5855 |
News Archive
Net sales for the third quarter of fiscal 2010 were $33,857,000 as compared to $38,240,000 for the same period of the prior fiscal year, a decrease of 11%. Net earnings for the third quarter of fiscal 2010 were $6,424,000 or $0.16 per diluted share, both decreases of 24%, compared to the third quarter of fiscal 2009. (Net earnings include $673,000 in Bioline acquisition costs or $0.01 per diluted share.) Diluted common shares outstanding for fiscal 2010 and 2009 were 41,151,000 and 41,191,000, respectively.
A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.
QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.
Acorda Therapeutics, Inc, today announced that data from preclinical studies show that Glial Growth Factor 2 (GGF2) promoted functional recovery following a permanent focal ischemic stroke.
› Verified 7 days ago
Lourdes Artola, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 21019 E Eldorado Dr, Aurora, CO 80013 Phone: 303-719-9281 | |
Mrs. Angelica Lopez Barton, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 4732 S Himalaya Ct, Aurora, CO 80015 Phone: 720-425-2911 | |
Mr. Trey Bell, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 17090 East Adriatic Drive, #b203, Aurora, CO 80013 Phone: 816-337-7200 | |
Kathleen Fleming, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 14701 E Exposition Ave, Aurora, CO 80012 Phone: 303-614-7461 | |
Ms. Nasima N/a Quazi, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2550 S Parker Rd, Aurora, CO 80014 Phone: 303-614-1400 | |
Miss Rebecca Louise Perez, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1290 Chambers Rd, Aurora, CO 80011 Phone: 303-504-1200 | |
Anastacia Clarice Chatman, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 14707 E 2nd Ave, Aurora, CO 80011 Phone: 303-375-9250 |